Novocure Ltd (NVCR) - Total Assets
Based on the latest financial reports, Novocure Ltd (NVCR) holds total assets worth $787.93 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Novocure Ltd - Total Assets Trend (2013–2025)
This chart illustrates how Novocure Ltd's total assets have evolved over time, based on quarterly financial data. Also see market cap of Novocure Ltd for the company's overall valuation and market capitalisation.
Novocure Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Novocure Ltd's total assets of $787.93 Million consist of 80.4% current assets and 19.6% non-current assets. Review Novocure Ltd (NVCR) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.9% |
| Accounts Receivable | $115.35 Million | 14.3% |
| Inventory | $41.11 Million | 5.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Novocure Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See NVCR share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novocure Ltd's current assets represent 80.4% of total assets in 2025, a decrease from 97.1% in 2013.
- Cash Position: Cash and equivalents constituted 12.9% of total assets in 2025, down from 93.1% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 14.3% of total assets.
Novocure Ltd Competitors by Total Assets
Key competitors of Novocure Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Biosynex
PA:ALBIO
|
France | €149.44 Million |
Novocure Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.90 | 1.47 | 9.00 |
| Quick Ratio | 2.70 | 1.41 | 8.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $414.08 Million | $346.00 Million | $929.36 Million |
Novocure Ltd - Advanced Valuation Insights
This section examines the relationship between Novocure Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.30 |
| Latest Market Cap to Assets Ratio | 2.41 |
| Asset Growth Rate (YoY) | -35.2% |
| Total Assets | $804.33 Million |
| Market Capitalization | $1.94 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Novocure Ltd's assets at a significant premium (2.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Novocure Ltd's assets decreased by 35.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Novocure Ltd (2013–2025)
The table below shows the annual total assets of Novocure Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $804.33 Million | -35.18% |
| 2024-12-31 | $1.24 Billion | +8.26% |
| 2023-12-31 | $1.15 Billion | -3.82% |
| 2022-12-31 | $1.19 Billion | +4.58% |
| 2021-12-31 | $1.14 Billion | +8.32% |
| 2020-12-31 | $1.05 Billion | +119.42% |
| 2019-12-31 | $479.45 Million | +41.10% |
| 2018-12-31 | $339.79 Million | +28.08% |
| 2017-12-31 | $265.30 Million | -5.95% |
| 2016-12-31 | $282.08 Million | -8.22% |
| 2015-12-31 | $307.34 Million | +160.73% |
| 2014-12-31 | $117.88 Million | -37.60% |
| 2013-12-31 | $188.91 Million | -- |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TT… Read more